Sprycel (Dasatinib) Patent Expiration, LOE Window & CMS Spending
Sprycel (Dasatinib) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2026-09-28, 10 AB generics, $780.5M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N021986 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2026-09-28 |
| Last Listed Patent or Exclusivity Date | 2026-09-28 |
| Orange Book Patents (*PED Extensions) | 2 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 10 |
| 2024 CMS Total Public Spend | $780.5M |
| 2024 Medicare Part D Spend | $518.3M |
| 2024 Medicaid Spend | $262.2M |
| Reported Wholesale Price Change (CA SB 17) | 12 WAC filings (max 20.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.